<DOC>
	<DOCNO>NCT01861340</DOCNO>
	<brief_summary>This research study do see combine investigational chemotherapy drug , MEDI-551 know anti-myeloma drug , Lenalidomide Dexamethasone reduce myeloma cancer stem cell .</brief_summary>
	<brief_title>Lenalidomide , Dexamethasone MEDI-551 Untreated Multiple Myeloma</brief_title>
	<detailed_description>To explore effect Lenalidomide , dexamethasone Medi-551 multiple myeloma cancer stem cell ( CSCs ) . Myeloma CSCs assess clonogenic assay bone marrow flow cytometry peripheral blood .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Age 18 100 year time screen Symptomatic , previously untreated ( exception corticosteroid ) secretory myeloma Written inform consent obtain patient/legal representative prior performing protocolrelated procedure , include screen evaluation Patient must agree take Lenalidomide low dose dexamethasone initial therapy . ECOG performance status 0 , 1 , 2 . Life expectancy &gt; 6 month Serum creatinine ≤ 2 ANC≥1000 Platelets ≥ 50,000 Total bilirubin ≤ 2 x ULN AST ( SGOT ) ALT ( SGPT ) ≤ 3 x ULN Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) Any condition , opinion investigator , would interfere evaluation investigational product interpretation patient safety study result . Concurrent enrollment another clinical study , except noninterventional , observational study . Any chemotherapy , immunotherapy , biologic , investigational , treatment multiple myeloma Lenalidomide dexamethasone . Previous monoclonal antibody ( mAb ) treatment specifically direct CD19 . History serious allergy reaction component MEDI551 formulation would prevent administration . Previous systemic cancer therapy myeloma . Any active secondary malignancy . Human immunodeficiency virus ( HIV ) positive serology acquire immune deficiency syndrome . Active hepatitis B define seropositivity hepatitis B surface antigen . Or patient positive hepatitis B core antibody titer . Patients hepatitis C antibody eligible provide elevate liver transaminase evidence active hepatitis . Documented current central nervous system involvement multiple myeloma . Previous medical history evidence intercurrent illness may , opinion investigator , compromise safety patient study . Diagnosis plasma cell leukemia Diagnosis POEMS syndrome Diagnosis Amyloidosis Diagnosis nonsecretory myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>